WARPTECHNEWS · LAB

Home AI Business Tech Archive

WARPTECH LAB NEWS

Warptech Lab News aggrega le notizie più rilevanti da oltre 700 fonti internazionali, con classificazione AI, TL;DR sintetici e timeline cluster su singole storie.

Navigazione

Home
Archivio
Editor's Brief
Cerca
Il tuo account
Newsletter tech/AI

Informazioni legali

Privacy Policy
Termini di servizio
Cookie Policy

© 2026 Sparktech S.R.L. — Tutti i diritti riservati. Sito gestito e manutenuto da Sparktech S.R.L.

Sede legale: Corso Libertà 55, 13100 Vercelli (VC), Italia · P.IVA / C.F. 02835910023 · Contatti: admin@warptechlab.com

Storia in 12 fonti

Eli Lilly acquires three vaccine developers for $3.8 billion

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Raccontata da

biopharmadive.com

pharmaceutical-technology.com

eluniversal.com.mx

koreaherald.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

qz.comStai leggendo1 mesi fa

Eli Lilly acquires three vaccine developers for $3.8 billion

The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

Timeline cronologica

martedì 26 maggio 2026·biopharmadive.com
Lilly dives into vaccine research with 3 biotech buyouts
Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.
martedì 26 maggio 2026·qz.com
Eli Lilly acquires three vaccine developers for $3.8 billion
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs

pharmaceutical-technology.com

1 mesi fa

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

Leggi questa versione → originale

biopharmadive.com1 mesi fa

Lilly dives into vaccine research with 3 biotech buyouts

Worth close to $4 billion combined, the acquisitions of Curevo, LimmaTech and Vaccine Co. signal plans by Lilly to build an infectious disease portfolio.

Leggi questa versione → originale

upi.com1 mesi fa

Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com

Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling nearly $4 billion.

Leggi questa versione → originale

cnbc.com1 mesi fa

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

Leggi questa versione → originale

statnews.com1 mesi fa

Eli Lilly to buy three small vaccine developers

Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.

Leggi questa versione → originale

martedì 26 maggio 2026·

endpoints.news

Three vaccine biotechs to be bought by Lilly for up to $3.8B

Lilly is making three acquisitions at once on Tuesday, for up to $3.8 billion total, to increase its presence in infectious disease. The pharma is buying Curevo, LimmaTech…

martedì 26 maggio 2026·

statnews.com

Eli Lilly to buy three small vaccine developers

Eli Lilly is acquiring three small vaccine developers, expanding its work in infectious diseases and giving the field a boost.

martedì 26 maggio 2026·

cnbc.com

Eli Lilly stock edges higher as company plans nearly $4 billion in vaccine deals

The deals are part of Eli Lilly’s effort to expand into infectious disease research and development.

martedì 26 maggio 2026·

pharmaceutical-technology.com

Eli Lilly to buy trio of vaccine developers in $3.8bn outlay - Pharmaceutical Technology

Via the deals, Lilly is buying biotechs with lead programmes in preventing shingles, bacteria, and Epstein-Barr Virus.

martedì 26 maggio 2026·

axios.com

Eli Lilly spending $3.8 billion to buy vaccine makers

GLP-1 riches are being repurposed to prevent infections.

martedì 26 maggio 2026·

upi.com

Eli Lilly announces acquisition of 3 vaccine makers in $4 billion deal - UPI.com

Eli Lilly announced Tuesday that it is acquiring Curevo Inc., LimmaTech Biologics AG and Vaccine Company, Inc., in deals totaling nearly $4 billion.

martedì 26 maggio 2026·

eluniversal.com.mx

Eli Lilly comprará 3 empresas fabricantes de vacunas por casi 4 mil mdd; ampliará investigación de enfermedades infecciosas | El Universal

En el cuarto trimestre de 2025, el gigante farmacéutico reconocido por sus medicamentos para adelgazar, reportó ingresos de 19 mil 290 mdd

martedì 26 maggio 2026·

benzinga.com

What's Going On With Eli Lilly Stock Tuesday? - Eli Lilly (NYSE:LLY)

Eli Lilly acquires Curevo, LimmaTech, and Vaccine Co. to expand its infectious disease portfolio and advance long-term disease prevention.

mercoledì 27 maggio 2026·

koreaherald.com

GC Biopharma sells US vaccine unit to Eli Lilly in $1.5b deal

GC Biopharma said Wednesday that it would transfer its US affiliate Curevo Vaccine to Eli Lilly and Company in a deal worth up to $1.5 billion. Under the agreem

mercoledì 27 maggio 2026·

startmag.it

Perché Eli Lilly fa scorpacciata di biotech focalizzate sui vaccini - Startmag

Eli Lilly accelera sul fronte delle acquisizioni e rimette al centro i vaccini, settore rimasto per anni ai margini della strategia

mercoledì 27 maggio 2026·

cnbc.com

Healthy Returns: Eli Lilly makes a new push into vaccines — here’s what to know

The drugmaker announced it will buy three privately held vaccine makers in deals worth almost $4 billion combined.